ALC1 is emerging as an important target for therapeutic intervention strategies in cancer, since ALC1 inactivation exacerbates the cytotoxic effects of clinical PARP inhibitors in HRD cancer cells19–23. This evidence concerns the gene PARP1 and cancer.